Spindle cell squamous carcinoma during braf inhibitor therapy for advanced melanoma: An aggressive secondary neoplasm of undetermined biologic potential

JAMA Dermatology

Volumn 150, Issue 5, 2014, Pages 575-577

  Cohen, Daniel N ^a   Lumbang, Wilfred A ^a   Boyd, Alan S ^a   Sosman, Jeffrey A ^a   Zwerner, Jeffrey P ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 903; DABRAFENIB; KERATIN; UNCLASSIFIED DRUG;

ACANTHOSIS; ADULT; BLEEDING; BRAIN RADIATION; CASE REPORT; CHILL; DRUG WITHDRAWAL; FACE INJURY; FATIGUE; FEMALE; FEVER; FIBROMA; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; IMMUNOREACTIVITY; LETTER; MELANOMA; METASTATIC MELANOMA; PAPILLOMATOSIS; PRIORITY JOURNAL; SPINDLE CELL CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY;

BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROTO-ONCOGENE PROTEINS B-RAF; RISK ASSESSMENT; SKIN NEOPLASMS; WITHHOLDING TREATMENT;

EID: 84901036145     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.7784     Document Type: Letter

References (6)

1. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2012;148(5):628-633.
2. Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11-e18.
3. Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15(3):249-259.
4. Viros A, Hayward R, Martin M, et al. Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma. J Invest Dermatol. 2013;133(1):274-276.
5. Alloo A, Garibyan L, Le Boeuf N, et al. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol. 2012;148(3):363-366.
6. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012;30(3):316-321.